Eli Lilly's Global Expansion Plan for Blockbuster Drug Mounjaro

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, and Mexico by 2025. With 900 million potential patients, the company aims to meet growing global demand alongside competitor Novo Nordisk. The drug is already approved in several regions.

Eli Lilly is set to expand the reach of its popular diabetes and weight-loss medication, Mounjaro, into sizable markets like China, India, Brazil, and Mexico by 2025, as announced by CFO Lucas Montarce at the Leerink Partners Global Healthcare Conference.

Montarce emphasized, "We're talking about 900 million patients that could benefit from Mounjaro," reflecting the significant market potential. Both Eli Lilly and Novo Nordisk have seen extraordinary global demand for their diabetes and weight-loss drugs, causing delays in entering emerging markets until they can adequately increase supply.

Mounjaro, also known as tirzepatide, is sold under the name Zepbound for obesity in the U.S., while maintaining the Mounjaro brand in the UK and Europe. The drug won approval from Chinese regulators last year, and Lilly CEO David Ricks announced a 2024 launch in India.

(With inputs from agencies.)